利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.044 秒)

    PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF INFLAMMATORY DISEASES OR IMMUNE DISEASES CONTAINING RAMALIN
    1.
    发明申请
    PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF INFLAMMATORY DISEASES OR IMMUNE DISEASES CONTAINING RAMALIN 审中-公开
    用于预防或治疗含有RAMALIN的炎症性疾病或免疫缺陷病毒的药物组合物

    公开(公告)号：US20130116324A1

    公开(公告)日：2013-05-09

    申请号：US13701113

    申请日：2011-06-02

    申请人： Joung Han Yim ,  Il Chan Kim ,  Sung Gu Lee ,  Doc Kyu Kim ,  Se Jong Han ,  Hyoung Seok Lee ,  Sung Jin Kim ,  Tai Kyoung Kim ,  Pil-Sung Kang ,  Heeyong Park ,  Ha Ju Park ,  Suhkneung Pyo

    发明人： Joung Han Yim ,  Il Chan Kim ,  Sung Gu Lee ,  Doc Kyu Kim ,  Se Jong Han ,  Hyoung Seok Lee ,  Sung Jin Kim ,  Tai Kyoung Kim ,  Pil-Sung Kang ,  Heeyong Park ,  Ha Ju Park ,  Suhkneung Pyo

    IPC分类号： A61K31/198 ,  A61K45/06

    CPC分类号： A61K31/198 ,  A61K31/45 ,  A61K45/06

    摘要： The present invention relates to the novel use (anti-inflammatory activity) of Ramalin isolated from the Antarctic lichen Ramalina terebrata, and more specifically to a pharmaceutical composition containing Ramalin as an active ingredient. Ramalin of the invention is a compound derived from natural material, has no toxicity or side effects, and inhibits the expression of inducible nitric oxide synthase (iNOS) in the transcription stage to significantly inhibit the production of nitric oxide (NO) that is a key mediator of inflammatory responses. In addition, it inhibits the activation of the inflammatory mediator NF-κB, inhibits p38 MAPK, ERK1/2 and JNK signaling pathways, and inhibits the expression of the LPS receptor TLR4, suggesting that Ramalin has an excellent anti-inflammatory effect. Thus, the composition containing Ramalin can be effectively used to fundamentally treat or prevent inflammatory diseases or immune diseases and to relieve or alleviate the symptoms of the diseases.

    摘要翻译： 本发明涉及从南极地衣Ramalina terebrata分离的Ramalin的新用途（抗炎活性），更具体地涉及含有Ramalin作为活性成分的药物组合物。 本发明的Ramalin是衍生自天然材料的化合物，没有毒性或副作用，并且在转录期抑制诱导型一氧化氮合酶（iNOS）的表达，以显着抑制作为关键的一氧化氮（NO）的产生 炎症反应的介质。 此外，它抑制炎症介质NF-κB的活化，抑制p38 MAPK，ERK1 / 2和JNK信号通路，并抑制LPS受体TLR4的表达，提示Ramalin具有优异的抗炎作用。 因此，含有Ramalin的组合物可以有效地用于从根本上治疗或预防炎性疾病或免疫疾病，并缓解或缓解疾病的症状。

    Pharmaceutical composition for preventing or treating hepatic fibrosis and cirrhosis containing ramalin
    8.
    发明授权
    Pharmaceutical composition for preventing or treating hepatic fibrosis and cirrhosis containing ramalin 有权
    用于预防或治疗含有马马隆的肝纤维化和肝硬化的药物组合物

    公开(公告)号：US09364452B2

    公开(公告)日：2016-06-14

    申请号：US14381490

    申请日：2012-02-29

    申请人： Joung Han Yim ,  Il Chan Kim ,  Se Jong Han ,  Hyoung Seok Lee ,  Hari Datta Bhattarai ,  Su-Geun Yang ,  Lee Don Hang

    发明人： Joung Han Yim ,  Il Chan Kim ,  Se Jong Han ,  Hyoung Seok Lee ,  Hari Datta Bhattarai ,  Su-Geun Yang ,  Lee Don Hang

    IPC分类号： A61K31/165 ,  A23L1/30 ,  A61K36/09

    CPC分类号： A61K31/165 ,  A23L33/105 ,  A23V2002/00 ,  A61K36/09

    摘要： There is provided a novel use of ramalin for preventing or treating liver diseases, and more specifically, a pharmaceutical composition for preventing or treating hepatic fibrosis or cirrhosis containing ramalin or a pharmaceutically acceptable salt thereof, and a functional food containing the same. It was confirmed that at the time of applying ramalin, which is a compound derived from Ramalina terebrata according to the present invention, to animal models, ramalin may remarkably suppress hepatic fibrosis and lower liver cirrhosis levels as compared to silymarin known as a liver cell protecting ingredient without cytotoxicity to normal liver cells, such that ramalin may be effectively used for preventing or treating hepatic fibrosis and liver cirrhosis.

    摘要翻译： 提供了一种用于预防或治疗肝脏疾病的新药，特别是用于预防或治疗含有罗马林或其药学上可接受的盐的肝纤维化或肝硬化的药物组合物和含有它们的功能性食品。 证实了在将根据本发明的衍生自Ramalina terebrata的化合物的马马林作用于动物模型时，与被称为肝细胞保护的水飞蓟素相比，马马林可显着抑制肝纤维化和降低肝硬化水平 成分对正常肝细胞没有细胞毒性，使得马马林可以有效地用于预防或治疗肝纤维化和肝硬化。

    PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING HEPATIC FIBROSIS AND CIRRHOSIS CONTAINING RAMALIN
    9.
    发明申请
    PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING HEPATIC FIBROSIS AND CIRRHOSIS CONTAINING RAMALIN 有权
    用于预防或治疗含有RAMALIN的肝纤维化和心律失调的药物组合物

    公开(公告)号：US20150031771A1

    公开(公告)日：2015-01-29

    申请号：US14381490

    申请日：2012-02-29

    申请人： Joung Han Yim ,  Il Chan Kim ,  Se Jong Han ,  Hyoung Seok Lee ,  Hari Datta Bhattarai ,  Su-Geun Yang ,  Lee Don Hang

    发明人： Joung Han Yim ,  Il Chan Kim ,  Se Jong Han ,  Hyoung Seok Lee ,  Hari Datta Bhattarai ,  Su-Geun Yang ,  Lee Don Hang

    IPC分类号： A61K31/165 ,  A23L1/30 ,  A61K36/09

    CPC分类号： A61K31/165 ,  A23L33/105 ,  A23V2002/00 ,  A61K36/09

    摘要： There is provided a novel use of ramalin for preventing or treating liver diseases, and more specifically, a pharmaceutical composition for preventing or treating hepatic fibrosis or cirrhosis containing ramalin or a pharmaceutically acceptable salt thereof, and a functional food containing the same. It was confirmed that at the time of applying ramalin, which is a compound derived from Ramalina terebrata according to the present invention, to animal models, ramalin may remarkably suppress hepatic fibrosis and lower liver cirrhosis levels as compared to silymarin known as a liver cell protecting ingredient without cytotoxicity to normal liver cells, such that ramalin may be effectively used for preventing or treating hepatic fibrosis and liver cirrhosis.

    摘要翻译： 提供了一种用于预防或治疗肝脏疾病的新药，特别是用于预防或治疗含有罗马林或其药学上可接受的盐的肝纤维化或肝硬化的药物组合物和含有它们的功能性食品。 证实了在将根据本发明的衍生自Ramalina terebrata的化合物的马马林作为动物模型的时候，与被称为肝细胞保护的水飞蓟素相比，马马酸可显着抑制肝纤维化和降低肝硬化水平 成分对正常肝细胞没有细胞毒性，因此马马林可以有效地用于预防或治疗肝纤维化和肝硬化。